Select novel small-molecule uPA potential inhibitors as anti-cancer agents against breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer metastasis is a major cause of cancer-related deaths worldwide.
• The urokinase type plasminogen activator (uPA) and its receptor (uPAR) system is crucial for cancer cell invasion and metastasis.
• Targeting the uPA/uPAR pathway presents a potential strategy for anticancer therapies.

Purpose of the Study:

• To investigate novel compounds as potential inhibitors of the uPA/uPAR pathway for cancer treatment.
• To evaluate the anticancer activity and efficacy of these compounds, particularly against triple-negative breast cancer.
• To explore the therapeutic potential of uPA/uPAR inhibitors in managing metastatic cancers.

Main Methods:

• Screening of novel compounds for bioactivity against uPA and uPAR.
• Assessment of inhibitory effects on uPA/uPAR interactions.
• Evaluation of compound efficacy and apoptotic pathway induction in MDA-MB-231 (triple-negative breast cancer) cells.
• Comparison with the chemotherapeutic drug Mitoxantrone.

Main Results:

• Identified novel uPA/uPAR inhibitors with low IC₅₀ values (as low as 1.4 μM) against MDA-MB-231 cells.
• Compounds KCO241 and KCO246 demonstrated selective anticancer activity and induced apoptosis in cancer cells.
• The efficacy of these compounds was comparable or superior to Mitoxantrone in specific assays.

Conclusions:

• Novel uPA/uPAR inhibitors exhibit significant potential as therapeutic agents for metastatic cancers.
• These compounds selectively target cancer cells and induce apoptotic cell death.
• Further preclinical in vivo studies are warranted to assess safety and therapeutic translation.